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The fatty acid -hydroxylation regiospecificity of
CYP4 enzymes may result from presentation of the ter-
minal carbon to the oxidizing species via a narrow chan-
nel that restricts access to the other carbon atoms. To
test this hypothesis, the oxidation of 12-iodo-, 12-bromo-,
and 12-chlorododecanoic acids by recombinant CYP4A1
has been examined. Although all three 12-halodode-
canoic acids bind to CYP4A1 with similar dissociation
constants, the 12-chloro and 12-bromo fatty acids are
oxidized to 12-hydroxydodecanoic acid and 12-oxodode-
canoic acid, whereas the 12-iodo analogue is very poorly
oxidized. Incubations in H2
18O show that the 12-hy-
droxydodecanoic acid oxygen derives from water,
whereas that in the aldehyde derives from O2. The alco-
hol thus arises from oxidation of the halide to an oxoha-
lonium species that is hydrolyzed by water, whereas the
aldehyde arises by a conventional carbon hydroxyla-
tion-elimination mechanism. No irreversible inactiva-
tion of CYP4A1 is observed during 12-halododecanoic
acid oxidation. Control experiments show that CYP2E1,
which has an -1 regiospecificity, primarily oxidizes 12-
halododecanoic acids to the -aldehyde rather than al-
cohol product. Incubation of CYP4A1 with 12,12-[2H]2-
12-chlorododecanoic acid causes a 2–3-fold increase in
halogen versus carbon oxidation. The fact that the order
of substrate oxidation (Br > Cl >> I) approximates the
inverse of the intrinsic oxidizability of the halogen at-
oms is consistent with presentation of the halide termi-
nus via a channel that accommodates the chloride and
bromide but not iodide atoms, which implies an effec-
tive channel diameter greater than 3.90 Å but smaller
than 4.30 Å.
Fatty acids are readily oxidized by cytochrome P450 enzymes
in an isoform-specific manner to hydroxy fatty acids and, in the
case of unsaturated fatty acids, also to epoxides (1–3). The
hydroxylation of fatty acids in general contributes to fatty acid
homeostasis, but the oxidation of arachidonic acid gives rise to
products that have specific functions in signaling pathways.
For example, the -hydroxylated product, 20-hydroxyeicosatet-
raenoic acid (20-HETE),1 is a vasoconstrictor (4, 5), whereas
the -1 hydroxylation product 19-HETE and some of the
arachidonic acid epoxides are vasodilators (2, 5, 6). The regio-
chemistry of oxidation of fatty acids, particularly arachidonic
acid, is therefore of critical physiological importance.
The oxidation of fatty acids at internal sites along the fatty
acid hydrocarbon chain is mediated by a variety of cytochrome
P450 enzymes. The -1 position on the carbon adjacent to the
terminal carbon of the hydrocarbon chain is the usual primary
default position for the oxidation of fatty acids by P450 en-
zymes not specifically evolved as fatty acid hydroxylases (7, 8).
Hydroxylation of the terminal () carbon does not occur, or is a
very minor product, with such P450 enzymes. This specificity
reflects the fact that the -1 position is intrinsically more
reactive than the terminal () position because a secondary
C-H bond is several Kcal weaker than a primary C-H bond, and
thus is more susceptible to oxidation by P450 enzymes (9, 10).
Furthermore, in steric terms, the -1 carbon is only second to
the terminal carbon in steric accessibility. The -hydroxylation
of fatty acids is therefore a difficult reaction that must be
actively promoted by the active site structure.
The CYP4 family of P450 enzymes is unique in that it pref-
erentially catalyzes the -hydroxylation of fatty acids. These
enzymes therefore reflect the evolution of a strategy that pre-
dominantly directs the reaction to the terminal carbon. We
have previously postulated that this strategy involves a con-
stricted access channel to the ferryl species that disfavors pres-
entation of any atom other than the terminal methyl for oxi-
dation (7). This hypothesis is supported by the fact that (a)
different chain length fatty acids are preferentially oxidized at
the  terminus, ruling out mechanisms that involve sensing
the distance of the -carbon from the carboxyl group (11); (b)
the oxidation of terminal triple bonds inactivates the CYP4
enzymes via a reaction that involves addition of the ferryl
oxygen to the terminal carbon of the triple bond, yielding a
ketene, rather than to the internal carbon, which would result
in heme alkylation (7, 12); and (c) placement of bulky substitu-
ents, such as a phenyl group, at the fatty acid terminus sup-
presses oxidation of the substrate (13).
In addition to hydrocarbon hydroxylation, P450 enzymes
catalyze a diversity of other reactions, including the oxida-
tion of heteroatoms to zwitterionic products: e.g. of trialkyl
amines to trialkyl amine oxides and dialkylsulfides to dial-
kylsulfoxides (14). However, P450 enzymes are powerful ox-
idative catalysts and evidence exists that they can oxidize not
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only nitrogen and sulfur functions but also the halogen atom
in aryl- and alkyliodides, bromides, and possibly even chlo-
rides. Conclusive evidence for oxidation of a halide atom is
only available for aryliodides. It has been demonstrated that
the P450-catalyzed, iodosobenzene-dependent oxidation of la-
beled iodobenzene results in the formation of labeled iodoso-
benzene (15). Using a substrate that stabilizes the iodoso
structure, Guengerich (16) has, furthermore, directly demon-
strated formation of the iodoso derivative in a normal P450-
catalyzed reaction. The evidence for bromide and chloride
oxidation is less direct. The oxidation of 1,2-dichloroethane
and propyl halides by liver microsomes produced a range of
products, including compounds whose formation is compati-
ble with (but does not require) a mechanism involving oxida-
tion of the halide atom (17, 18). The formation of a metabolite
in the oxidation of CCl4 that reacts as an electrophilic chlo-
ride atom has also been postulated from the formation of a
p-chlorophenol in the presence of a phenol trap (19).
We report here preparation of the 12-iodo-, 12-bromo-, and
12-chlorododecanoic acids and analysis of their oxidation by
recombinant CYP4A1, a rat enzyme that highly favors -hy-
droxylation of dodecanoic (lauric) acid. The hypothesis behind
this study is that the halogen atom becomes the “” position in
these substrates, and therefore its oxidation, if possible, should
be enforced by the same active site features that promote
-hydroxylation of dodecanoic acid. The results have provided
important insights into the mechanism used by the CYP4 fam-
ily of enzymes to favor - over -1 hydroxylation of fatty acids.
EXPERIMENTAL PROCEDURES
Materials—Ampicillin, -aminolevulinic acid, glycerol, lysozyme,
DLPC, glutathione, catalase, NADPH, and dodecanoic acid were from
Sigma. 11-Dodecenoic acid was from NuChek Prep (Elysian, MN), and
Tris from Fisher Scientific. [1-14C]Dodecanoic acid (55 mCi/mmol, 18
mM) was from American Radiolabeled Chemicals (St. Louis. MO).
CYP4A1 was expressed and purified as previously reported (20). Hu-
man CYP2E1 ( P450 reductase  cytochrome b5 Supersomes
TM) and
control insect cell membranes were purchased from Gentest-BD Bio-
sciences. The human NADPH-cytochrome P450 reductase cDNA was
provided by Stephen M. Black and the protein was expressed and
purified as previously described (20). Purified rat liver cytochrome b5
was a gift from Lester Bornheim (University of California, San Fran-
cisco). Human liver cytochrome b5 was purchased from Promega (Fitch-
burg, WI).
Preparation of Probes—12-Iodododecanoic acid (3) was synthesized
from 12-hydroxydodecanoic acid using the procedure of Apparu et al.
(21) (trimethylsilylchloride/NaI) to afford 3 as a white solid (m.p. 59.0–
60.0 °C; literature m.p. 59.0–61.0 °C (22)). 12-Bromododecanoic acid (2)
was synthesized from 12-hydroxydodecanoic acid using the procedure of
Jocelyn and Polar (23) (HBr/H2SO4) to afford 2 as a white solid (m.p.
52.0–53.0 °C; literature m.p. 52.0 (24) and 53.0 °C (25)). 12-Chlorodo-
decanoic acid (1) was synthesized from 2 using the procedure of Peyrat
et al. (26) (trimethylsilylchloride/dimethylformamide) to afford 1 as a
white solid (m.p. 40.0–41.0 °C; literature m.p. 39.5–40.5 °C (27)).
12,12-[2H]2-12-Chlorododecanoic acid (7) was synthesized from 12-
hydroxydodecanoic acid in four steps beginning with esterification of
the free acid with diazomethane and protection of the alcohol as the
t-butyldimethylsilyl ether (90% yield over two steps). Reduction of the
ester with lithium aluminum deuteride (89% yield) was followed by
chlorination of the alcohol with triphenylphosphine/carbon tetrachlo-
ride (79% yield). Acidic cleavage of the silyl ether was followed by
oxidation to the carboxylic acid 7 using 8 N Jones’ Reagent. Purification
by flash chromatography (silica gel, 10% ethyl acetate in hexanes, 0.5%
acetic acid) afforded 7 (60% yield) as a white solid (m.p. 38.0–39.0 °C).
1H NMR (500 MHz, CDCl3),  1.20–1.45 (14H, m), 1.59 (2H, quint, J1 
7.5 Hz), 1.71 (2H, quint, J1  7.5 Hz), 2.31 (2H, t, J1  7.5 Hz), 3.50
(0.04H, residual CH2Cl, t, J1  7.2 Hz), 9.80 (1H, br s).
13C NMR (125
MHz, CDCl3),  24.6, 26.8, 28.8, 29.0, 29.1, 29.30, 29.35, 29.38, 32.4,
34.0, 44.4 (quint, 1JC-D 22.8 Hz), 180.5. GC/MS: 238/236 (M .
, 0.2/0.4),
195/193 (1.3, 4.0), 129 (12.0), 85 (10.5), 73 (67.3), 71 (20.3), 60 (100), and
55 (41.9).
12-Oxododecanoic acid (4) was prepared by the procedure of Corey
and Suggs (28). A suspension of 12-hydroxydodecanoic acid (1.07 g, 5
mmol) in 12 ml of CH2Cl2 was combined with pyridinium chlorochro-
mate (1.63 g, 7.5 mmol) in 10 ml of CH2Cl2 and the resulting mixture
was stirred under nitrogen at25 °C for 2 h. Diethyl ether (100 ml) was
then added and the black reaction mixture was filtered. The filtered
ether fraction was passed through Florisil, the ether was removed
under vacuum at a rotary evaporator, and the residue was purified by
silica gel flash chromatography. The GC-MS of the trimethylsilyl (TMS)
derivative of aldehyde 4 had a retention time of 10.40 min and a
molecular ion at m/z 286.
Spectroscopic Methods—Reduced CO-difference spectra and spectro-
scopic substrate binding studies were performed on a Varian Cary 1E
UV-visible dual-beam spectrophotometer. Absolute spectra were re-
corded on a Hewlett-Packard 8452 diode array spectrophotometer. Both
instruments were equipped with temperature control accessories. The
cytochrome P450 content was determined by the method of Omura and
Sato (29). To obtain substrate binding difference spectra, the probes
dissolved in methanol were titrated into the CYP4A (0.5 M) solution
using a 10-l Hamilton syringe, resulting in a final sample volume
change of less than 2% and introduction of less than 2% methanol into
the solution. All spectra were obtained at 25 °C. The spectral binding
constant Ks was determined from the hyperbolic plot of the respective
differences between the absorbance at 417 and 390 nm versus the
ligand concentration.
Measurement of CYP4A1 Hydroxylation Activity—CYP4A1 - and
-1 hydroxylation was measured by mixing the stock phosphate buffer
solutions of 10 g of DLPC, 3.12–15 pmol of CYP4A1, 31.25–250 pmol
of cytochrome P450 reductase, 3.13–25 pmol of cytochrome b5, and 5 g
of catalase. This mixture was incubated for 10 min at room temperature
before 50 mM Tris (pH 7.4) containing 250 mM NaCl and 10% glycerol
was added to a final volume of 490 l. Finally, 5 l of a 10 mM solution
of [1-14C]dodecanoic acid (final concentration 100 M) was added. The
reaction was started after an additional incubation time of 2 min at
37 °C by addition of 10 l of 100 mM NADPH. The mixture was incu-
bated at 37 °C. Aliquots (50 l) were removed at time periods between
0 and 10 min and were quenched by adding 100 l of ice-cold 94:6
acetonitrile:acetic acid (v/v). The precipitated proteins were pelleted out
by centrifugation in a microcentrifuge for 2 min and the samples were
analyzed by HPLC coupled to a flow scintillation analyzer.
HPLC Dodecanoic Acid Hydroxylation Assay—The hydroxydode-
canoic acids were separated from dodecanoic acid on a C18 Alltech
Econosil column (3.2  150 mm) operated isocratically with a 90:10
mixture of acetonitrile (0.1% trifluoroacetic acid):water (0.1% trifluoro-
acetic acid). The HPLC system was coupled to a Packard Radiomatic
Flow-One model A500 radioisotope detector. Under these conditions,
the hydroxydodecanoic acids eluted at 3.3 min, whereas dodecanoic acid
eluted at 4.6 min.
Assay for Inactivation of CYP4A1—A two-stage procedure was used
to evaluate time-dependent inactivation of CYP4A1 in the presence of
12-halododecanoic acids. In the first stage, 10-fold concentrated incu-
bation solutions were incubated at 37 °C with 0–200 M concentrations
of each of the three 12-halododecanoic acids either in the presence or
absence of 10 mM NADPH. At specified time intervals, an aliquot (5 l)
was diluted 10-fold by the addition of 50 l of a second stage assay
mixture consisting of the same buffer, 10 mM NADPH, and 100 M
[1-14C]dodecanoic acid. The diluted mixture was incubated for a further
11 min at 37 °C and was then terminated by the addition of ice-cold 94:6
acetonitrile:acetic acid (v/v). The precipitated proteins were pelleted by
centrifugation in a microcentrifuge for 2–5 min, and the samples were
stored at 20 °C until analyzed by HPLC.
Measurement of CYP4A Oxidation Activity by GC-MS—CYP4A1
-hydroxylation was measured by mixing together 10 g of DLPC,
12.5 pmol of CYP4A1, 125 pmol of cytochrome P450 reductase, 12.5
pmol of cytochrome b5, and 5 g of catalase, followed by incubation of
the mixture for 10 min at room temperature. The required amount of
substrate (dodecanoic acid, 12-chlorododecanoic acid (1), 12-bromo-
dodecanoic acid (2), 12-iodododecanoic acid (3), or 12,12-[2H]2-12-
chlorododecanoic acid (7): usually 100 M final concentration) was
then added, followed by sufficient 50 mM Tris (pH 7.4) buffer contain-
ing 250 mM NaCl, 0.02% sodium cholate, and 20% glycerol to bring
the volume to 245 l. After an additional incubation time of 2 min at
37 °C, the reaction was started by adding 5 l of 100 mM NADPH. The
mixture was then incubated at 37 °C for a period of 0–150 min. The
reaction was terminated by adding 20 l of ice-cold 6 M HCl, imme-
diately mixing the contents of the vial and placing it on ice. The
internal standard (phenylacetic acid, 100 M final concentration) was
then added and the samples were mixed again before they were
transferred to solid-phase extraction.
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Solid-phase Extraction—In a modification of a published procedure
(30), Bond-Elut C18 cartridges (100 mg, 3 ml, Varian) were sequentially
washed with 2 ml of CHCl3, methanol, and water. The incubation
samples were transferred to the cartridges and the solvent was slowly
pushed through under nitrogen pressure. The cartridges were then
washed with 2 ml of water and were thoroughly dried for 1 h by nitrogen
at 20 p.s.i. The analytes were eluted into 5-ml glass screw-top tubes
with Teflon-lined caps with two 1-ml aliquots of CHCl3. The CHCl3 was
evaporated to dryness under a stream of nitrogen. The samples were
then converted to the trimethylsilyl derivatives by incubation with 50
l of N,O-bis(trimethylsilyl)trifluoroacetamide) at 70 °C for 10–15 min.
The derivatized samples were allowed to cool, vortexed, and transferred
to sealed Teflon-capped glass vials for either manual or autoinjection
into the GC-MS.
GC-MS—Product analysis was preformed on an Agilent GC6850
Series II GC coupled to an Agilent 5973 Network Mass Spectrometry
Detector. This GC-MS system was equipped with an Agilent 7683
Series autosampler interfaced with a PC computer running Agilent
MSD Productivity ChemStation Revisions D.01.02 software. A 30-m
DB-5 capillary column coupled with a 5-m guard column (Agilent,
USA) (0.25 mm inner diameter, 0.1 m film) was used with helium as
the carrier gas at a head pressure of 50 p.s.i. Injection (3 l) was in
the split mode (10:1) with the all-glass injector temperature at
250 °C. The GC oven temperature was programmed for 1 min at 70 °C
followed by a rise to 170 °C at 25 °C/min, to 200 °C at 5 °C/min, and
to 280 °C at 20 °C/min. The oven was finally held at 280 °C for 5 min.
The MS source and interface were maintained at 250 and 280 °C,
respectively, and a solvent delay of 4 min was used. The MS was set
for a full scan from 30 to 500 mass units. The analytes were identified
from a total ion chromatogram.
The following are the retention times and molecular masses of the
trimethylsilyl derivatives of the authentic standards of the substrates
and products: dodecanoic acid-TMS, 8.62 min, MR 272; 1, TMS, 12.14
min, MR 306; 2, TMS, 12.98 min, MR 350, 352; 3, TMS, 13.79 min, MR
398; 4, TMS, 11.40 min, MR 286; 5, diTMS, 13.50 min, MR 374; 6,
diTMS, 12.82 min, MR 360; 7, TMS, 12.14 min, MR 308; 8, diTMS, 12.15
min, MR 360; 9, TMS, 8.42 min, MR 270.
CYP2E1 Oxidation Activity by GC-MS—Standard incubations (250
l total volume) consisted of 50 pmol of CYP2E1 microsomes (human
CYP2E1  P450 reductase  cytochrome b5 Supersomes®), substrate
(100 M), DLPC, superoxidase dismutase, catalase, and NADPH (2 mM)
in 0.1 M phosphate buffer (pH 7.4). The substrate (dodecanoic acid, 1 or
7) was coated on the walls of an Eppendorf tube with methanol and the
methanol was removed by a stream of nitrogen before the other com-
ponents were added. The NADPH was added to initiate the reaction
after preincubation of the other components for 5 min at 37 °C. The
incubation was continued for 2.5 h at 37 °C and was then quenched with
6 M HCl. The internal standard (phenylacetic acid, 100 M final con-
centration) was then added and the samples were mixed again before
they were transferred to solid-phase extraction for GC-MS analysis.
Measurement of CYP4A1 Activity in 18O-Labeled Water—The proce-
dure was nearly identical to that used for the measurement of CYP4A1
activity in normal buffer. To prepare the 18O-buffer (265 l), 1.6 M Tris
(pH 7.4 at 0 °C, 7.8 l) was mixed with 3.5 mg of NaCl, 50 l of glycerol,
1 l of sodium cholate (5% in H2O), and finally 188.5 l of H2
18O. In a
separate tube, the CYP4A1 system was prepared by mixing CYP4A1
(12.5 pmol), P450 reductase (125 pmol), cytochrome b5 (12.5 pmol),
DLPC (10 l, 0.5 g/liter), and catalase (2.5 l, 10 g/liter) in their storage
phosphate buffer together to a total volume of 15.6 l. This CYP4A1
system was mixed with the 18O-buffer and incubated for 10 min at 0 °C
followed by 10 min at 25 °C. The substrate (1 or 2) was then added and
the mixture was preincubated at 37 °C for 2 min before NADPH was
added. The final 18O-content was 87.5%. The incubation was contin-
ued for 2.5 h at 37 °C and was then quenched with 6 M HCl. The internal
standard (phenylacetic acid, 100 M final concentration) was then
added and the samples mixed before they were transferred to solid-
phase extraction for GCMS analysis. In a different protocol, after the
incubation was finished, the quenching step was omitted and during
the solid phase extraction, the solid phase extraction column was not
washed with water to minimize possible exchange of the 18O in metab-
olites with 16O water.
RESULTS
Binding of 12-Halododecanoic Acids to CYP4A1—12-Chloro-,
12-bromo-, and 12-iodododecanoic acids (Fig. 1) were titrated
into a cuvette containing a solution of ferric CYP4A1 and the
spectroscopic changes were recorded. Each of these three 12-
halododecanoic acids caused the appearance of a binding spec-
trum (Fig. 2). The difference between the absorbance at 390
and 417 nm as a function of the ligand concentration gave rise
to a hyperbolic plot from which the spectroscopic dissociation
constant Ks was calculated (Fig. 2, inset). These measurements
gave the following values for the dissociation constants of the
three halododecanoic acids: 12-chloro, Ks  11.8 M; 12-bromo,
Ks  7.9 M; and 12-iodo, Ks  6.0 M. Comparison of these
values with Ks  30 M for dodecanoic acid itself indicates
that all three 12-halododecanoic acids bind to CYP4A1 with
similar affinities but 3–4-fold more tightly than the parent
dodecanoic acid (20).
Products Formed in the CYP4A1-catalyzed Oxidation of 12-
Halododecanoic Acids—Analysis of the products formed in
incubations of CYP4A1 with the 12-halododecanoic acids iden-
tified three catalytically generated products: 12-hydroxydode-
canoic acid (6), 12-oxododecanoic acid (4), and 1,12-dode-
canedioic acid (5) (Fig. 3a, Table I). These peaks were the only
ones present that were not also present in an incubation from
which NADPH had been omitted. The identities of the prod-
ucts, after conversion to the trimethylsilyl derivatives, were
confirmed by chromatographic and mass spectrometric com-
parison with similarly derivatized authentic samples. 11-Do-
decenoic acid (9) was not detected as a metabolite. A small
FIG. 1. Structures of the substrates
and products discussed in this study.
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amount of dodecanoic acid was observed in all the incubations
at time 0, but its concentration did not change with incubation
time. This suggests that the dodecanoic acid is present as a
contaminant in one of the incubation components. To confirm
that the trace dodecanoic acid observed is actually a contami-
nant, four sets of control experiments were separately per-
formed: (a) without NADPH, (b) without the substrate, (c)
without the CYP4A1 system, and (d) under anaerobic condi-
tions. In all of these control experiments, dodecanoic acid was
detected and its ratio versus the substrate remained constant
(data not shown). In view of the control experiments, the source
of the contaminating dodecanoic acid is likely to be the DLPC.
Rates of Halododecanoic Acid Metabolism by CYP4A1—The
rates of formation of 12-hydroxydodecanoic acid, 12-oxodode-
canoic acid, and 1,12-dodecanedioic acid were followed as a
function of time of incubation to estimate the relative rates of
metabolism of the three 12-halododecanoic acids. As shown in
Fig. 4a and summarized in Table II, the formation of 12-
oxododecanoic acid occurs substantially more rapidly with 12-
chlorododecanoic acid than with 12-bromododecanoic acid. For-
mation of this product is hardly observed with 12-
iodododecanoic acid (the amount of 12-oxododecanoic acid
observed is on par with that obtained in a control experiment
without NADPH in the incubation). As shown in Fig. 4b, the
formation of 1,12-dodecanedioic acid occurs with a similar
trend as that seen for the formation of 12-oxododecanoic acid,
as might be expected if the diacid is obtained by secondary
oxidation of the 12-oxododecanoic acid metabolite. With 12-
iodododecanoic acid formation of 1,12-dodecanedioic acid was
not observed and is therefore not plotted on Fig. 4b.
A related but less marked trend is observed for oxidation of
the 12-halododecanoic acids to 12-hydroxydodecanoic acid.
Thus, the 12-hydroxy product is formed at a similar rate with
the 12-chloro- and 12-bromododecanoic acids, but only to a low
extent with 12-iodododecanoic acid (Fig. 4c).
If one plots the oxidation of the 12-halododecanoic acids, as
judged by the combined formation of the three metabolites, one
obtains the plot in Fig. 4d. It is clear from these results, and
most clearly shown by the final plot, that 12-chlorododecanoic
acid is oxidized more rapidly than 12-bromododecanoic acid,
whereas 12-iodododecanoic acid is hardly a substrate
for CYP4A1.
Source of the Oxygen in the 12-Halododecanoic Acid Metab-
olites—To determine the origin of the hydroxyl group in the
products formed from the oxidation of 12-chloro- and 12-bro-
mododecanoic acid, these substrates were incubated with the
enzyme system in a medium estimated to contain 87.5% of
H2
18O. Mass spectrometric analysis of the products from these
12-halododecanoic acids indicated that the hydroxyl oxygen
atom in the 12-hydroxydodecanoic acid from both 12-halodode-
canoic acids was 75% 18O-labeled. This conclusion derives
from a comparison of the relative intensities of the peaks atm/z
345 and 347, which correspond to M-15 for the unlabeled and
labeled 12-hydroxylauric acid diTMS derivatives, respectively
(Fig. 5a). This value is consistent with the percent of 18O label
in the water used for the incubation. In contrast, in both cases,
oxygen in the 12-oxododecanoic acid product was only slightly
labeled or not labeled at all, as shown by the fact that the
parent ion peak is at m/z 271, which corresponds to M-15 for
the 12-oxododecanoic acid TMS derivative (Fig. 5b). If the al-
dehyde oxygen were labeled with 18O, this peak should have
been at m/z 273. In a control experiment in which we simply
incubated 12-oxododecanoic acid in H2
18O, it was found that
the aldehyde oxygen of 12-oxododecanoic acid readily ex-
changes with the oxygen of water. Therefore a different
work-up protocol was tried in which the quenching and wash-
ing steps in the solid phase extraction procedure were omitted
to minimize solvent (H2
16O) exchange in the work-up stage.
The results showed again that the hydroxyl oxygen atom in the
12-hydroxydodecanoic acid from both 12-halododecanoic acids
was 75–80% 18O-labeled and the oxygen in the 12-oxodode-
canoic acid product was 11% labeled, presumably as a result
of a small extent of exchange with the solvent during incuba-
tion in the H2
18O medium. Furthermore, about 10% 18O label
was observed in the 1,12-dodecanedioic acid that results from
the further oxidation of the aldehyde, consistent with the ratio
seen with the aldehyde itself.
Assay for Inactivation of CYP4A1—The possible formation of
an electrophilic intermediate in the oxidation of the 12-halodo-
decanoic acids suggested that CYP4A1 might be inactivated
during turnover of these substrates through alkylation of the
heme or protein. 10-Fold concentrated solutions of the complete
CYP4A1 system were therefore preincubated with each of the
three 12-halododecanoic acids and the residual activity of the
enzyme after a 10-fold dilution was evaluated with the stand-
ard dodecanoic acid hydroxylation assay as a function of time.
No inactivation in excess of that obtained in the absence of
12-chlorododecanoic acid was observed over a preincubation
period of up to 25 min with up to 200 M concentrations of
12-chlorododecanoic acid. 12-Bromo- and 12-iodododecanoic ac-
ids were also tested and no inactivation was apparent, al-
though the data points were more scattered than in the case of
12-chlorododecanoic acid and a small amount of inactivation
would not have been detected.
CYP2E1 Oxidation of 12-Chlorododecanoic—CYP2E1 is
known to catalyze the -1 hydroxylation of fatty acids and
was therefore examined as a control. This enzyme was first
tested with dodecanoic acid and the /-1 hydroxylation ratio
was found to be 0.16. Thus, 86% of the oxidation occurred at
the -1 position and 14% at the  position. We then tested
this enzyme with 12-chlorododecanoic acid, for which the
overall conversion to products was 26% as compared with
52% for CYP4A1 (Table I). The products observed in the
reaction were again 12-hydroxydodecanoic, 12-oxodode-
canoic, and 1,12-dodecanedioc acids. Unexpectedly, given the
-1 regiospecificity of the enzyme, 12-hydroxydodecanoic acid
FIG. 2. Spectrum of the binding of 12-iodododecanoic acid to
CYP4A1. The spectrum of the protein before binding of a substrate
(dashed line) and after binding of 12-iodododecanoic acid (solid line).
The inset shows the Ks values for the three 12-halododecanoic acids.
The spectroscopic binding studies were carried out in the following
buffer: 50 mM Tris (pH 7.4) buffer containing 250 mM NaCl, 0.02%
sodium cholate, and 20% glycerol.
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constituted a large proportion of the products. However, the
CYP2E1 enzyme employed for these studies was the commer-
cially available human CYP2E1 that is provided in baculovi-
rus-transfected insect cell microsomes. As the insect cell mi-
crosomes contain no other P450 enzyme but do contain other
enzymes, we incubated the enzyme preparation with 12-ox-
ododecanoic acid itself and found that it is readily reduced to
12-hydroxydodecanoic acid in the presence of NADPH. In a
FIG. 3. GC-MS of the products formed in the incubation of CYP4A1 with 12-chlorododecanoic acid. a, GC-MS trace of the products;
b, mass spectrum of product 4 at 11.40 min; and c, mass spectrum of product 6 at 12.82 min.
TABLE I
Incubations of 1, 2, 3, and 7 with recombinant human CYP4A1 and baculovirus microsomes containing recombinant human CYP2E1
All the data were obtained after a 2.5-h incubation.
4 5 6 Conversion /(-1)
%
CYP4A1
1 30  1 11  2 11  1 52  3 0.27  0.02
2 14  1 11  1 13  1 38  1 0.51  0.04
3 1.2  0.2 1.5  0.1 2.9  0.1 5.6  0.3 1.12  0.16a
7 10  1 10  1 12  1 33  1 0.61  0.04
CYP2E1
1 10  1 5.9  0.4 10  0.3b 26  1 NAc
a This value is not reliable because the low turnover for 3 yielded data points with relatively large error limits
b 6 appears to arise from the -1 hydroxylation product.
c NA, not available.
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control experiment, insect cell microsomes not expressing
CYP2E1 were found not to have catalytic activity toward
lauric acid or 12-chlorododecanoic acid.
Product formation in incubations of this same enzyme prep-
aration with 12,12-[2H]2-12-chlorododecanoic acid was greatly
attenuated because of a deuterium isotope effect. Nevertheless,
we observed a roughly 4–5% (1 nmol using 25 pmol of pro-
tein) conversion of the deuterated starting material to prod-
ucts. The molecular mass of the 12-hydroxydodecanoic acid
formed in the reaction was 361, as indicated by a peak at m/z
346 (M-15, data not shown), in agreement with retention of
only one of the two original deuterium atoms. This finding
indicates that the alcohol product from 12,12-[2H]2-12-chlo-
rododecanoic acid arose by reduction of 12-[2H]12-oxodode-
canoic acid, the aldehyde obtained by normal -1 hydroxylation
of the substrate by CYP2E1. If the alcohol had arisen from
direct oxidation of the halide, both deuterium atoms would
have been preserved in the product, yielding 12,12-[2H]2-12-
hydroxydodecanoic acid with a molecular mass of 362, as was
found with CYP4A1.
DISCUSSION
The binding of substrates to the resting ferric state of P450
enzymes can usually be monitored by spectroscopic changes
associated with substrate binding (31, 32). These changes nor-
mally involve changes in the coordination of the heme iron,
such as dissociation of the distal water ligand or coordination of
an atom of the substrate with the iron, which result in shifts
between the pentacoordinated and hexacoordinated states of
the enzyme (31, 32). As shown here, the three 12-halodode-
canoic acids, like dodecanoic acid itself, cause a readily moni-
tored change in the spectrum of CYP4A1 involving a decrease
in absorption at 417 nm and a corresponding increase at 390
FIG. 4. Product formation as a function of time in incubations of the complete CYP4A1 system with 12-chloro- (●), 12-bromo- (f),
and 12-iodododecanoic acid (Œ). a, formation of 12-oxododecanoic acid; b, formation of 1,12-dodecanedioic acid; c, formation of 12-hydroxydo-
decanoic acid; and d, combined formation of 12-oxododecanoic acid, 1,12-dodecanedioic acid, and 12-hydroxydodecanoic acid. Because of differences
in incubation conditions, the final conversion ratio was slightly different from that of the single-time point (i.e. 2.5 h) incubation.
TABLE II
Turnover numbers for the metabolites (min1)
The turnover numbers were estimated from the data in Fig. 4, the
fact that the incubations contained 12.5 pmol of CYP4A1 and 25 nmol
of 12-halododecanoic acid, and the incubation time of 150 min
4 5 6 Total
1 6.0 2.4 1.3 9.7
2 2.3 1.3 1.2 4.8
3 0.3 NDa 0.3 0.6
a ND, not determined.
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nm (Fig. 2). This type of spectroscopic shift, known as a Type I
binding spectrum (31), strongly suggests that the three sub-
strates, like dodecanoic acid itself, promote a shift from the
hexacoordinated to the pentacoordinated state of the heme
iron, presumably by promoting dissociation of a distal water
ligand. Titration of the spectroscopic change indicates that all
three 12-halododecanoic acids bind more tightly than dodeca-
noic acid itself (Ks of 6–12 M compared with 30 M for
dodecanoic acid). Tighter binding is consistent with the fact
that all the 12-halododecanoic acids involve extension of the
dodecanoic acid chain by the addition of a hydrophobic atom:
the nonaromatic lipophilicity constants for Cl, Br, and I sub-
stituents (water versus octanol) are, respectively,   0.39,
0.60, and 1.00 (33). Binding to P450 enzymes is generally
enhanced by increased lipophilicity (34).
The principal surprise of this study was that the 12-chloro
and 12-bromo derivatives of dodecanoic acid were oxidized by
CYP4A1, whereas the 12-iodo derivative was almost inert de-
spite its demonstrated ability to bind to the enzyme and to
promote dissociation of the distal water ligand. Two types of
oxidative reactions were observed. The first is a conventional
reaction in which the enzyme hydroxylates the halogen-substi-
tuted carbon to give the 12-halo-12-hydroxydodecanoic acid,
which undergoes intramolecular elimination of HX (X  halide
ion) to yield the aldehyde. The resulting aldehyde is then par-
tially oxidized in a second step by CYP4A1 via a well estab-
lished reaction to the acid (35, 36). This sequence of events is
confirmed by the observation that the aldehyde and the diacid
formed from 12-chlorododecanoic acid in a medium in which
the water is 87.5% 18O-labeled incorporate only a trace of the
18O label.
CYP4A1 is an -hydroxylase that preferentially oxidizes
fatty acids at the  (i.e. terminal) carbon atom. However, this
specificity is not absolute and a small amount of the -1 hy-
droxylated fatty acid (8) is also produced (11). In the case of
dodecanoic acid, the ratio of - to -1 hydroxylation is as high
as 40:1, although this specificity decreases for myristic acid,
which is two carbons longer, to a ratio of 3:1 (11). In both cases,
the CYP4A enzymes favor the thermodynamically difficult
-hydroxylation over oxidation of the intrinsically more reac-
tive -1 position. To explain this selectivity, we have proposed
that the active site involves presentation of the terminal atom
to the oxidizing ferryl species via a narrow access channel that
favors oxidation of the terminal carbon at the expense of the
-1 carbon (7). In this model, the small amount of -1 hydroxy-
lation results from a limited degree of active site flexibility that
occasionally allows the -1 carbon to become accessible to the
ferryl species. The results with the 12-halododecanoic acids are
readily understood within this proposed active site paradigm
(Fig. 6). The halogen in the 12-halododecanoic acids is effec-
tively the terminal atom of the chain, so that aldehyde produc-
tion from the 12-halododecanoic acids is the result of an -1
hydroxylation process. The observed decrease in formation of
the aldehyde product from the 12-halododecanoic acids in the
order Cl  Br  I correlates with the increasing size of the
-halogen atom; i.e. the larger the terminal atom, the less
“play” there is in the active site and the less the enzyme is able
to circumvent the halide atom to oxidize the -1 position. The
alternative explanation that the C-H bond next to the chloride
is broken more readily than that next to the bromide is contra-
dicted by a body of literature that shows that the bond strength
is weaker, and reactivity of the C-H bond higher, if a bromide
rather than a chloride is present on the carbon (37).
Even more impressive and definitive is the finding that 12-
chlorododecanoic acid and 12-bromododecanoic acid are oxi-
dized by CYP4A1 to the corresponding alcohols, whereas the
12-iodo is again very poorly oxidized by this pathway. The
mechanism of this oxidation is unambiguously established by
the demonstration, using H2
18O, that the hydroxyl group in the
product derives essentially quantitatively from the water of the
FIG. 6. Proposed mechanism for discrimination between the
chloro, bromo, and iodo terminal atom in the 12-halododecanoic
acids. The CYP4A1 ferryl species is represented by the Fe  O in the
figure. The increasing size of the halide atoms relative to the diameter
of the channel is illustrated schematically and the Van der Waal’s
radius of H, Cl, Br, and I is cited. This mechanism directly relates to the
- versus -1 specificity of CYP4A1 and other CYP4 family enzymes.
FIG. 5. Mass spectra of (a) the 12-hydroxydodecanoic acid and (b) 12-oxododecanoic acid obtained from an incubation of
12-chlorododecanoic acid with the complete CYP4A1 system in 18O-labeled medium.
CYP4A1 Oxidation of 12-Halododecanoic Acids 22703
 at UQ Library on October 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
medium. The alcohol therefore must arise by a mechanism
independent of formation of the aldehyde by -1 hydroxylation,
as only minor (11%) 18O-incorporation is observed for the alde-
hyde as a result of exchange with the solvent. It is evident that
the mechanism involves direct oxidation of the halide by the
P450 ferryl intermediate, producing the corresponding oxoha-
lonium species (Scheme 1) that is displaced by water to give the
alcohol with incorporation of an oxygen from the medium. The
hydrolysis of oxohalonium substituents is a well established
chemical reaction (38).
The view that oxidation of the terminal halide atom and
hydroxylation of the carbon to which it is attached are compet-
ing reaction pathways for the ferryl intermediate is supported
by studies with 1,12-[2H2]12-chlorododecanoic acid. Oxidation
of this deuterated substrate gives similar products to oxidation
of the non-deuterated analogue, with the alcohol retaining both
deuterium atoms, but the ratio of the alcohol and aldehyde plus
acid products indicates that oxidation of the halide atom in-
creased approximately 2–3-fold. This metabolic switching phe-
nomenon, which reflects the higher energy of the C-2H than
C-H bond, is a characteristic of a P450 reaction in which the
two sites of reaction compete for the oxidizing ferryl species
(39). In a related experiment, we have shown that the 12-
halododecanoic acids are oxidized by CYP2E1, a nonspecific
P450 enzyme that primarily catalyzes the -1 hydroxylation of
dodecanoic acid, to the corresponding aldehyde product with
only minimal direct formation of the alcohol product. Although
alcohol product was formed, control experiments and experi-
ments with the 12,12-dideuterated 12-chlorododecanoic acid
clearly establish that with this enzyme the initial P450 product
is the aldehyde that is subsequently reduced by an adventitious
aldehyde dehydrogenase activity in the baculovirus micro-
somes. This emphasizes the critical role that is played by the
CYP4A1 protein in channeling the catalytic turnover toward
oxidation of the terminal atom in the fatty acid chain.
The most interesting finding is that the order of oxidation of
the halogen in the 12-halododecanoic acid is Br  Cl I. This
is particularly informative because the oxidation potentials of
the halides follow a somewhat reverse order: i.e. iodide is more
oxidizable than bromide, which in turn is more oxidizable than
chloride (40). Thus, intrinsic reactivity would predict that oxi-
dation of the 12-halododecanoic acids would occur in the order
I  Br  Cl. This paradox is readily explained by the hypoth-
esis that the  specificity of the enzyme is determined by
presentation of the terminal atom of the fatty acid chain for
oxidation through a sterically restricted channel or opening.
The van der Waal’s radius of a chloro atom (1.8 Å) is slightly
smaller than that of a methyl (2.0 Å), and the radius of a bromo
substituent (1.95 Å) is approximately the same size, but that of
an iodide (2.15 Å) is somewhat larger (41). Thus, if the terminal
atom must be presented via a tightly constrained channel, it is
not surprising that the chloride is readily presented and (de-
spite its high oxidation potential) oxidized to the oxochloro-
nium substituent. The bromide can also be presented, but with
less clearance, so that although its oxidation to the -alcohol is
not affected (it is actually increased a little compared with the
chloride), oxidation to the aldehyde is attenuated because of
the increased difficulty in accessing the carbon to which the
halide is attached. Finally, the iodide is apparently sufficiently
large that it no longer fits into the access channel and, if at all,
is very poorly oxidized. As already noted, the van der Waal’s
radii of the bromo and iodide atoms are 1.95 and 2.15 Å,
respectively. This suggests that the orifice through which the
terminal atom must be presented for oxidation by the ferryl
species has an effective diameter larger than 3.90 Å but smaller
than 4.30 Å. A very tight tolerance of the presentation channel
is implied by the  specificity of the enzyme, as the looser the
fit the more the enzyme would favor the thermodynamically
easier -1 hydroxylation.
As already noted, all three 12-halododecanoic acids displace
the distal water ligand, or at least cause the spectroscopic
change characteristic of a Type II binding event, even though
the iodide apparently cannot approach the heme iron atom
close enough to physically displace the water ligand from the
iron. This suggests that a conformational change or a signifi-
cant change in active site polarity triggers loss of the water
ligand or, alternatively, that access to the ferryl species only
becomes restricted during catalysis, perhaps as a result of
conformational changes associated with the active site reorga-
nization that attends oxygen activation (42). We have recently
reported that computational docking of imidazole ligands to
cytochrome P450cam roughly predicts inhibitory activity but
neither the docking nor catalytic results correlate with the
spectroscopically measured binding of the ligand (43). These
combined results suggest that a greater allowance may need to
be made for the dynamic nature of the P450 active site in
interpreting spectroscopically determined changes in the distal
iron ligand.
Formation of the oxochloronium and oxobromonium sub-
stituents, both of which are excellent leaving groups, could
result not only in their displacement by water to give the
alcohol metabolite but also in reaction with an active site
nucleophile, resulting in inactivation of the enzyme. Alkyl oxo-
halonium species such as these are known to chemically react
with nucleophiles (38, 44). However, analysis of the protein
activity after preincubation with the 12-halododecanoic acids
indicates that there is no loss of activity over and above that
observed in the absence of the halogenated probe molecules.
Thus, either water rapidly traps the oxohalonium intermedi-
ate, either within the active site or after its dissociation into the
medium, before it can react with a critical protein nucleophile,
or the activated metabolite only reacts with non-essential
amino acid residues in the protein.
In summary, oxidation of the 12-halododecanoic acids by
CYP4A1 has provided (a) unambiguous evidence that halogens,
including iodide, bromide, and chloride, can be oxidized by
SCHEME 1. Mechanism proposed for
oxidation of the 12-halododecanoic
acids to 12-hydroxydodecanoic acid
with incorporation of the oxygen
from water into the hydroxyl group
of the product (-oxidation), and to
12-oxododecanoic acid and eventu-
ally 1,12-dodecanedioic acid with in-
corporation of oxygen from molecu-
lar oxygen but not from water (-1
hydroxylation).
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P450 enzymes to the corresponding 12-oxohalonium products
that are readily hydrolyzed to the alcohols, and (b) direct evi-
dence that the -regiospecificity of CYP4A1, and presumably
all the other CYP4A enzymes, is enforced by requiring the
terminal atom of the chain to be threaded for oxidation through
a narrow channel that tolerates a methyl, chloro, or bromo but
not iodo atom. This implicates an effective channel diameter
larger than 3.90 Å but smaller than 4.30 Å.
Acknowledgment—We acknowledge early preliminary work on this
problem using protein isolated from rat liver microsomes by
Dr. Claire Cajacob.
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